Real-World data shows High-Dose tafamidis may slow nerve damage in ATTR-CM patients
NCT ID NCT06393465
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical records of 50 people with a rare heart condition called ATTR-CM to see if high-dose tafamidis (Vyndamax) slows nerve damage. Researchers compared how fast nerve problems got worse before and after starting the drug. The goal was to see if the medication works in everyday medical practice, not just in controlled studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tafamidis (Vyndamax)
- What this could lead to
- If successful, this could confirm that high-dose tafamidis helps slow nerve damage in people with mixed-phenotype ATTR-CM, supporting its use in real-world care.
- What could go wrong
- This is a small, completed study that only looked back at existing medical records, not a controlled trial. Results may not apply to all patients, and tafamidis does not cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.